A Panoramic View of the Kallikrein Family: From Structure and Function to Disease and Drug Development

The kallikrein family is a diverse group of serine proteases with important roles in physiology, disease biology, biomarker discovery, and therapeutic development. Originally recognized for their role in blood pressure regulation through kinin generation, kallikreins are now studied across oncology, inflammation, dermatology, cardiovascular biology, neuroscience, and drug discovery.

Introduction and Historical Perspective

The kallikrein story began in the early 20th century with the discovery of a hypotensive substance in human urine. In 1930, Kraut, Frey, and Werle identified this factor in pancreatic extracts and named it “kallikrein,” derived from the Greek word kallikreas, meaning pancreas. Subsequent studies showed that kallikreins act by releasing kinins from kininogen substrates, establishing the kallikrein-kinin system as a fundamental physiological regulatory pathway.

For decades, kallikrein research focused mainly on plasma kallikrein, also known as KLKB1, and tissue or glandular kallikrein, KLK1. With molecular cloning and genomic sequencing, the field expanded significantly. The human genome project enabled the identification of 15 kallikrein-related peptidase genes, KLK1 through KLK15, clustered on chromosome 19q13.4.

Genomic Organization and Evolution

Chromosomal Localization and Gene Cluster

All 15 human KLK genes are tightly clustered within an approximately 320 kb region on chromosome 19q13.4. This clustering is unusual among serine protease families and supports the idea that the KLK family expanded through gene duplication events. The genes are arranged in a tandem array, with KLK1 at the centromeric end and KLK15 at the telomeric end.

Figure 1. Genomic organization of the kallikrein locus on chromosome 19q13.4, showing the 15 KLK genes in chromosomal order, along with promoter regions and conserved elements.

Gene Structure and Regulatory Elements

KLK genes typically contain five coding exons with conserved exon-intron boundaries, reflecting their shared evolutionary origin. Their promoter regions include regulatory elements responsive to hormones, vitamins, cytokines, and other signaling molecules. These regulatory mechanisms support tissue-specific expression and responsiveness to physiological cues.

Epigenetic modifications, especially DNA methylation, further shape KLK expression patterns in both normal and pathological contexts.

Evolution and Orthologs

Comparative genomic studies have identified kallikrein orthologs across vertebrates, although the number of family members varies by species. Expansion of the KLK family appears to be a mammalian adaptation, with primates having the highest number of paralogs. This expansion likely supported functional specialization in reproduction, skin homeostasis, and neural processing.

Protein Structure and Biochemical Properties

General Structural Features

Kallikreins are secreted serine proteases of approximately 25-30 kDa. They are synthesized as pre-proenzymes. The pre-signal peptide directs secretion, while the pro-peptide maintains zymogen inactivity. Mature kallikrein enzymes contain approximately 230-250 amino acids and share the characteristic serine protease fold.

Figure 2. Three-dimensional structure of a typical kallikrein, showing the conserved serine protease fold, catalytic triad, activation pocket, and surface loops that influence substrate specificity.

Catalytic Mechanism and Specificity

All kallikreins share the conserved catalytic triad of histidine, aspartate, and serine residues required for proteolytic activity. However, differences in substrate-binding pockets create distinct cleavage preferences among family members.

• Plasma kallikrein/KLKB1: Prefers Arg ↓ X bonds and cleaves high-molecular-weight kininogen to release bradykinin.
• Tissue kallikrein/KLK1: Cleaves low-molecular-weight kininogen at Arg ↓ X and Met ↓ X bonds, producing lysyl-bradykinin, also known as kallidin.
• KLK2-15: Show diverse substrate preferences, with many favoring basic residues such as arginine or lysine at the P1 position. Some members, including KLK3 and KLK7, display chymotrypsin-like or elastase-like preferences.

Activation Mechanisms and Cascades

Kallikreins frequently operate within proteolytic cascades. In the plasma kallikrein-kinin system, Factor XII autoactivates on negatively charged surfaces and then activates plasma prekallikrein. In the tissue kallikrein system, pro-KLK1 is activated by convertases or autoactivation. Many KLKs can also activate other KLK zymogens, forming amplification loops.

Glycosylation and Post-Translational Modifications

Many kallikreins contain N-linked glycosylation sites that influence protein stability, secretion, and activity. KLK3, also known as PSA, contains a single N-glycosylation site that is important for secretion and stability. Other modifications include phosphorylation and complex formation with endogenous inhibitors.

Physiological Functions

Cardiovascular Regulation

The classical function of the kallikrein-kinin system is blood pressure regulation through kinin production. Bradykinin and kallidin bind to B2 receptors, promoting vasodilation, vascular permeability, and hypotension. These peptides may also contribute to cardioprotective processes, including reduced ischemic injury and angiogenesis.

Inflammation and Pain

Kinins are potent inflammatory mediators that can induce pain, vasodilation, and edema. Kallikreins participate in both the initiation and resolution of inflammatory responses through interactions with complement, coagulation, and cytokine networks.

Skin Homeostasis and Desquamation

KLK5, KLK7, and KLK14 form a proteolytic cascade in the epidermis that regulates corneocyte shedding by degrading desmosomal proteins. This process must be tightly controlled by endogenous inhibitors such as LEKTI to maintain normal skin barrier function.

Neural Function

Several KLKs, especially KLK6 and KLK8, are expressed in the central nervous system. They are involved in neural plasticity, myelination, and neurodegenerative processes. KLK8, also known as neuropsin, has been linked to hippocampal learning and memory.

Reproductive System Functions

Multiple kallikreins contribute to reproductive biology. In seminal fluid, KLK2, KLK3, and KLK4 process semenogelins, contributing to post-ejaculation semen liquefaction. KLK1, KLK6, and other kallikreins may also participate in follicle rupture, endometrial remodeling, implantation, cervical ripening, and membrane rupture.

Mineral Metabolism

KLK1 generates lysyl-bradykinin in the kidney, stimulating prostaglandin synthesis and promoting sodium excretion. This activity contributes to fluid and electrolyte balance.

Kallikreins in Disease

Cancer

Kallikreins, particularly KLK3/PSA, have had a major impact on cancer diagnostics and monitoring. PSA screening transformed prostate cancer detection, although limitations in specificity and overdiagnosis remain important considerations.

Beyond diagnostics, KLK2, KLK3, and KLK4 can contribute to prostate cancer progression by activating growth factors, degrading extracellular matrix components, and modulating signaling pathways. In ovarian cancer, multiple KLKs, including KLK5-8, KLK10-11, and KLK13-15, show altered expression. Some kallikreins are associated with poor outcome, while others correlate with more favorable prognosis.

In breast cancer, KLK3 is expressed in a subset of tumors, while other KLKs show stage- and subtype-specific changes. KLK14 overexpression has been associated with aggressive phenotypes.

Figure 3. Kallikrein involvement in cancer progression, including invasion, metastasis, angiogenesis, and proliferation.

Mechanistic Roles in Cancer

• Growth factor activation and receptor cleavage
• Extracellular matrix degradation that facilitates invasion
• Protease-activated receptor signaling
• Angiogenesis modulation
• Regulation of apoptotic pathways and chemoresistance

Inflammatory and Skin Diseases

In Netherton syndrome, loss-of-function mutations in SPINK5, which encodes LEKTI, lead to unregulated KLK5, KLK7, and KLK14 activity. This causes severe skin barrier defects, inflammation, and atopy. Altered kallikrein-inhibitor balance may also contribute to psoriasis and atopic dermatitis.

In hereditary and acquired angioedema, uncontrolled plasma kallikrein activity can lead to excessive bradykinin production.

Cardiovascular Disorders

Reduced urinary kallikrein excretion has been associated with essential hypertension in some populations. Alterations in kallikrein-kinin system components may also influence myocardial remodeling, fibrosis, functional recovery after injury, and atherosclerosis-related inflammation.

Neurodegenerative Diseases

KLK6 and KLK8 can process amyloid precursor protein and may influence amyloid-beta peptide biology. KLK6 can also degrade alpha-synuclein, linking kallikrein biology to synucleinopathies. In multiple sclerosis, KLK6 levels have been associated with disease activity and may contribute to demyelination through proteolytic damage.

Other Conditions

Altered KLK expression may contribute to reproductive dysfunction in polycystic ovarian syndrome. KLK1 and bacterial kallikrein-like enzymes may also participate in periodontal inflammation and tissue destruction.

Diagnostic Applications

PSA as a Paradigm and Limitation

PSA testing is one of the most successful cancer biomarker applications, although its clinical use continues to raise questions related to specificity and overdiagnosis. Refinements include PSA density, PSA velocity, free-to-total PSA ratio, PSA isoforms, and kallikrein panels such as the 4Kscore, which combines total PSA, free PSA, intact PSA, and hK2.

Multi-Kallikrein Panels for Other Cancers

Ovarian cancer detection strategies combining CA125 with kallikreins such as KLK6 and KLK7 have shown potential for improved sensitivity and specificity. Similar multi-marker approaches are being explored for breast, lung, and pancreatic cancers.

Future Directions in Diagnostics

• Circulating tumor cell-associated kallikreins
• Extracellular vesicle-derived kallikreins
• Activity-based probes for functional assessment
• Point-of-care devices using kallikrein substrates

Therapeutic Targeting and Drug Development

Plasma Kallikrein Inhibitors

Several plasma kallikrein-targeted therapies have been developed for hereditary angioedema. Approved agents include ecallantide, a recombinant Kunitz-type inhibitor; lanadelumab, a fully human monoclonal antibody that inhibits plasma kallikrein; and berotralstat, an oral small-molecule inhibitor.

KLK3 / PSA-Targeted Approaches

PSA-targeted strategies include PSA-activated prodrugs designed to release cytotoxic agents in PSA-expressing tumors, PSA-directed immunotherapies, and PSA activity inhibitors. Development remains challenging because of functional redundancy and the complexity of protease networks.

KLK4-7 Inhibitors for Skin Diseases

Therapeutic strategies for inflammatory skin diseases include LEKTI-derived peptides, small-molecule inhibitors targeting KLK5 and KLK7, and topical approaches that combine barrier repair with kallikrein inhibition.

Cancer Therapeutic Strategies

• Monoclonal antibodies targeting specific kallikreins or activated forms
• Small-molecule inhibitors, including approaches targeting KLK4 in prostate cancer bone metastasis
• Antisense oligonucleotides and siRNA-based gene-silencing strategies
• Dual-targeting agents that combine kallikrein inhibition with other therapeutic pathways

Challenges in Kallikrein-Targeted Therapy

• Redundancy and cascades: Inhibiting one kallikrein may be bypassed by related proteases.
• Selectivity: Achieving specificity among closely related serine proteases remains difficult.
• Delivery: Tissue-specific targeting is especially challenging in neurological applications.
• Biological complexity: Kallikreins can have context-dependent protective and pathological roles.

Future Perspectives and Conclusions

The kallikrein field continues to evolve through systems biology, structural biology, biomarker development, and therapeutic innovation. Integrating kallikrein networks with other proteolytic systems, including matrix metalloproteinases and coagulation factors, may provide a more complete understanding of their physiological and pathological roles.

Advances in cryo-EM and computational modeling may reveal dynamic aspects of kallikrein function, including allosteric regulation and complex formation with substrates or inhibitors. Personalized medicine approaches may also benefit from studying KLK gene polymorphisms and regulatory mechanisms that influence disease risk, progression, and therapeutic response.

Beyond proteolysis, kallikreins may influence signaling through protease-activated receptors and growth factor receptors. Their interaction with microbial proteases in the skin and gastrointestinal tract is another emerging area of research.

References

1. Borgono, C. A., & Diamandis, E. P. (2004). The emerging roles of human tissue kallikreins in cancer. Nature Reviews Cancer, 4(11), 876-890.
2. Clements, J., et al. (2004). The human kallikrein gene family: a diversity of expression and function. Molecular and Cellular Endocrinology, 217(1-2), 1-20.
3. Debela, M., et al. (2008). Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biological Chemistry, 389(6), 623-632.
4. Emami, N., & Diamandis, E. P. (2007). Human tissue kallikreins: a road under construction. Clinical Biochemistry, 40(18), 1360-1374.
5. Goettig, P., et al. (2010). Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). Biochimie, 92(11), 1546-1567.
6. Lundwall, Å., & Brattsand, M. (2008). Kallikrein-related peptidases. Cellular and Molecular Life Sciences, 65(13), 2019-2038.
7. Paliouras, M., et al. (2007). Human kallikrein-related peptidases: roles in carcinogenesis. Expert Opinion on Therapeutic Targets, 11(8), 1049-1067.
8. Prassas, I., et al. (2015). Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nature Reviews Drug Discovery, 14(3), 183-202.
9. Sotiropoulou, G., et al. (2009). Kallikrein-related peptidases: new biomarkers and targets for cancer therapy. Expert Review of Molecular Diagnostics, 9(5), 457-471.
10. Yousef, G. M., & Diamandis, E. P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocrine Reviews, 22(2), 184-204.